Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
306 Leser
Artikel bewerten:
(1)

Nasdaq Stockholm AB: Listing of Elicera Therapeutics AB, on Nasdaq First North Growth Market (243/21)

Nasdaq Stockholm AB has assessed that Elicera Therapeutics AB, company
registration number 556966-4955, fulfills Nasdaq First North Growth Market's
listing requirements. 

Provided that Elicera Therapeutics AB, applies for admission to trading of its
shares on Nasdaq First North Growth Market Sweden, first day of trading is
expected to be June 11, 2021. 

Shares



Short name:               ELIC          
----------------------------------------------------------------
Maximum number of shares to be listed: 19,782,000       
----------------------------------------------------------------
ISIN code:               SE0015382080      
----------------------------------------------------------------
Round Lot:               1            
----------------------------------------------------------------
Order book ID:             226310         
----------------------------------------------------------------
Company Registration Number:      556966-4955       
----------------------------------------------------------------
Market segment:             First North STO/8    
----------------------------------------------------------------
Tick Size table:            MiFID II tick size table
----------------------------------------------------------------
MIC code:                SSME          
----------------------------------------------------------------
Trading currency:            SEK           
----------------------------------------------------------------



Equity Rights



Short name:           ELIC TO1                    
--------------------------------------------------------------------------------
Maximum number of warrants to  7,750,000                   
 be listed:                                   
--------------------------------------------------------------------------------
Terms:              2 TO1 entitles to 1 share at a subscription  
                 price of SEK 11.60              
--------------------------------------------------------------------------------
Subscription period:       November 1, 2022 - November 30, 2022      
--------------------------------------------------------------------------------
Last trading day:        November 28, 2022               
--------------------------------------------------------------------------------
ISIN code:            SE0015988233                  
--------------------------------------------------------------------------------
Round Lot:            1                       
--------------------------------------------------------------------------------
Order book ID:          226311                     
--------------------------------------------------------------------------------
Market segment:         First North STO/8               
--------------------------------------------------------------------------------
Tick Size table:         MiFID II tick size table            
--------------------------------------------------------------------------------
MIC code:            SSME                      
--------------------------------------------------------------------------------
Trading currency:        SEK                      
--------------------------------------------------------------------------------



Classification



Code Name    
-----------------
20  Health Care
-----------------
2010 Health Care
-----------------




This information is distributed at the request of the Certified Adviser, G&W
Fondkommission. For further information, please call G&W Fondkommission on +46
8 503 000 50.
© 2021 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.